Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically proven diagnosis of non-small cell lung cancer~* positive for the ALK fusion gene (test provided by a central laboratory)~* must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug~* tumors must be measurable~Exclusion Criteria:~* prior treatment with PF-02341066~* current treatment in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-02341066 (Type: EXPERIMENTAL): None
- Pemetrexed or Docetaxel (Type: ACTIVE_COMPARATOR): Investigator selection of either pemetrexed or docetaxel as the active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).